
GenSight Biologics Secures Israeli Authorization for Early Access to LUMEVOQ
Israel Grants Regulatory Authorization for Early Access Use of GS010/LUMEVOQ in ND4-LHON Patients GenSight Biologics, a biopharmaceutical company dedicated to the development and commercialization of innovative gene therapies for retinal…












